Interstitial lung disease associated to erlotinib treatment: a case report.
BACKGROUND
Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described.


METHODS
We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease.


CONCLUSIONS
Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.
Del Castillo
Yolanda
Y
Unidad de Cuidados Intensivos, Hospital de Sant Pau i Santa Tecla, Rambla Vella, 14, 43003, Tarragona, Spain. castilloduran@hotmail.com.
Espinosa
Paulina
P
Bodí
Fernanda
F
Alcega
Raquel
R
Muñoz
Emma
E
Rabassó
Carlos
C
Castander
David
D